参考文献/References:
[1] Emerging Risk Factors Collaboration, Di Angelantonio E, Kaptoge S,et al. Association of cardiometabolic multimorbidity with mortality[J].JAMA,2015,314(1):52-60.DOI:10.1001/jama.2015.7008.
[2] Zinman B, Wanner C, Lachin JM,et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes[J].N Engl J Med,2015,373(22):2117-2128.DOI:10.1056/NEJMoa1504720.
[3] Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications[J].Diabet Med,2010,27(2):136-142. DOI:10.1111/j.1464-5491.2009.02894.x.
[4] Chao EC, Henry RR. SGLT2 inhibition--a novel strategy for diabetes treatment[J].Nat Rev Drug Discov,2010,9(7):551-559. DOI:10.1038/nrd3180.
[5] Savarese G, D'Amore C, Federici M,et al. Effects of dipeptidyl peptidase 4 inhibitors and sodium-glucose linked cotransporter-2 inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis[J].Int J Cardiol,2016,220:595-601. DOI:10.1016/j.ijcard.2016.06.208.
[6] Roden M, Weng J, Eilbracht J,et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial[J].Lancet Diabetes Endocrinol,2013,1(3):208-219. DOI:10.1016/S2213-8587(13)70084-6.
[7] Häring HU, Merker L, Seewaldt-Becker E,et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial[J].Diabetes Care,2013,36(11):3396-3404. DOI:10.2337/dc12-2673.
[8] Kalra S, Singh V, Nagrale D. Sodium-glucose cotransporter-2 inhibition and the glomerulus: a review[J].Adv Ther,2016,33(9):1502-1518.DOI:10.1007/s12325-016-0379-5.
[9] Wu JH, Foote C, Blomster J,et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic reviewand meta-analysis[J].Lancet Diabetes Endocrinol,2016,4(5):411-419. DOI:10.1016/S2213-8587(16)00052-8.
[10] Sha S, Polidori D, Heise T,et al. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus[J].Diabetes Obes Metab,2014,16(11):1087-1095. DOI:10.1111/dom.12322.
[11] Patel A, ADVANCE Collaborative Group, MacMahon S,et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus(the ADVANCE trial): a randomised controlled trial[J].Lancet,2007,370(9590):829-840.DOI: 10.1016/s0140-6736(07)61303-8.
[12] Shyangdan DS, Uthman OA, Waugh N. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis[J].BMJ Open,2016,6(2):e009417. DOI:10.1136/bmjopen-2015-009417.
[13] Maliha G, Townsend RR. SGLT2 inhibitors: their potential reduction in blood pressure[J].J Am Soc Hypertens,2015,9(1):48-53. DOI:10.1016/j.jash.2014.11.001.
[14] ACCORD Study Group, Cushman WC, Evans GW,et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus[J].N Engl J Med,2010,362(17):1575-1585. DOI:10.1056/NEJMoa1001286.
[15] Sattar N, McLaren J, Kristensen SL,et al. SGLT2 inhibition and cardiovascular events: why did EMPA-REG outcomes surprise and what were the likely mechanisms?[J].Diabetologia,2016,59(7):1333-1339. DOI:10.1007/s00125-016-3956-x.
[16] Liu T, Takimoto E, Dimaano VL,et al. Inhibiting mitochondrial Na+/Ca2+ exchange prevents sudden death in a Guinea pig model of heart failure[J].Circ Res,2014,115(1):44-54. DOI:10.1161/CIRCRESAHA.115.303062.
[17] Marx N, McGuire DK. Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular eventsin high-risk patients with diabetes mellitus[J].Eur Heart J,2016,37(42):3192-3200.DOI:10.1093/eurheartj/ehw110.
[18] Cherney DZ, Perkins BA, Soleymanlou N,et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus[J].Circulation,2014,129(5):587-597.DOI:10.1161/CIRCULATIONAHA.113.005081.
[19] Cherney DZ, Perkins BA, Soleymanlou N,et al. Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes[J].Kidney Int,2014,86(5):1057-1058.DOI:10.1038/ki.2014.246.
[20] Inzucchi SE, Zinman B, Wanner C,et al. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials[J].Diab Vasc Dis Res,2015,12(2):90-100. DOI:10.1177/1479164114559852.
[21] Doehner W, Rauchhaus M, Ponikowski P,et al. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure[J].J Am Coll Cardiol,2005,46(6):1019-1026.DOI:10.1016/j.jacc.2005.02.093.
[22] Hsueh WA, Lyon CJ, Quiñones MJ. Insulin resistance and the endothelium[J].Am J Med,2004,117(2):109-117.DOI:10.1016/j.amjmed.2004.02.042.
[23] Lin B, Koibuchi N, Hasegawa Y,et al. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice[J].Cardiovasc Diabetol,2014,13:148. DOI:10.1186/s12933-014-0148-1.
[24] Tahara A, Kurosaki E, Yokono M,et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice[J].Eur J Pharmacol,2013,715(1-3):246-255. DOI:10.1016/j.ejphar.2013.05.014.